When is a bisphosphonate drug holiday considered, and what factors influence this decision?

• A. After 1 year of therapy; based on patient preference
• B. After 3-5 years of oral therapy or 3-6 years of IV therapy, depending on fracture risk and BMD
• C. Never; therapy should continue indefinitely
• D. After 10 years; regardless of risk

Answer: (B)

The idea behind a bisphosphonate holiday is to balance ongoing fracture protection with the goal of reducing rare long-term risks and allowing some normal bone remodeling to resume. These drugs stay bound in bone for years, so their effect persists after stopping, but continuing therapy indefinitely can modestly increase certain risks (like rare atypical femur fractures or osteonecrosis of the jaw) and may offer diminishing additional benefit over time in some patients.

That’s why a holiday is commonly considered after a few years of therapy. For an oral bisphosphonate, about three to five years of treatment is a typical threshold, while for an intravenous form, such as zoledronic acid, about three to six years is often used. The exact timing isn’t a fixed rule—it depends on how strong the patient’s fracture risk is and what their bone mineral density shows.

If the fracture risk is high or bone density remains concerning (for example, a low T-score or a high FRAX estimate, previous vertebral or hip fractures, advanced age, or other risk factors), a holiday might be shortened or therapy continued, with close monitoring. If the risk appears lower and the patient tolerates therapy well, a holiday is more likely to be considered, with plans to re-evaluate over time. Other influences include the specific bisphosphonate used, renal function (which affects drug choice and dosing), adherence, and patient preferences.